COMMUNIQUÉS West-GlobeNewswire
-
Menlo Therapeutics’ Successful Phase 2 Clinical Trial of Serlopitant Demonstrates Reduction of Pruritus Associated with Psoriasis
10/12/2018 - 13:00 -
Emerald Health Sees License Expansion of Pure Sunfarms Cannabis Production Operation to 687,000 Square Feet, one of Largest Production Capacities in Canada
10/12/2018 - 13:00 -
Axovant Reports Results of Exploratory Phase 2 Clinical Study of Nelotanserin in Lewy Body Dementia Patients Experiencing REM Sleep Behavior Disorder
10/12/2018 - 13:00 -
Active Biotech provides updated information about the company's financial position
10/12/2018 - 12:31 -
LHC Group and LifePoint Health expand partnership with two acquisitions in North Carolina and Virginia
10/12/2018 - 12:30 -
Emblem launches new line of Oil Capsules
10/12/2018 - 12:30 -
BeiGene to Present Clinical Data on Anti-PD-1 Antibody Tislelizumab at the European Society for Medical Oncology Immuno-Oncology Congress
10/12/2018 - 12:05 -
Achillion Interim Clinical Trial Data and Strategic Update Planned for Dec 17th, 2018
10/12/2018 - 12:00 -
OraSure Technologies Announces 2019 Annual Meeting Date
10/12/2018 - 12:00 -
Orphazyme expects to announce results of full data set for Niemann-Pick disease Type C (NPC) Phase II/III trial in Q1 2019
10/12/2018 - 10:38 -
German Clinic Orders Second Acarix CADScor®System to Further Boost Patient Capacity
10/12/2018 - 10:01 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of December 5, 2018
10/12/2018 - 08:10 -
EssilorLuxottica : Nombre total de droits de vote et d'actions composant le capital social au 5 décembre 2018
10/12/2018 - 08:10 -
EssilorLuxottica: Disclosure of Share Capital and Voting Rights Outstanding as of November 30, 2018
10/12/2018 - 08:07 -
EssilorLuxottica : Nombre total de droits de vote et d'actions composant le capital social au 30 novembre 2018
10/12/2018 - 08:07 -
Mereo BioPharma to Present at The BMO Prescriptions for Success Healthcare Conference on 12 December 2018
10/12/2018 - 08:00 -
Bio-on and Hera create Lux-on the new challenge to produce bioplastic from CO2.
10/12/2018 - 07:59 -
Bio-on et Hera insufflent la vie à Lux-on Toute dernière initiative pour produire des bioplastiques à base de CO2.
10/12/2018 - 07:59 -
Basilea Pharmaceutica AG : Continued strong Cresemba® (isavuconazole) U.S. sales performance triggers CHF 10 million milestone payment to Basilea
10/12/2018 - 07:16
Pages